A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner

There is an urgent need for better therapeutic options for advanced melanoma patients, particularly those without the BRAF(V600E/K) mutation. In melanoma cells, loss of TRIM16 expression is a marker of cell migration and metastasis, while the BRAF inhibitor, vemurafenib, induces melanoma cell growth...

Descripción completa

Detalles Bibliográficos
Autores principales: Sutton, Selina K., Carter, Daniel R., Kim, Patrick, Tan, Owen, Arndt, Greg M., Zhang, Xu Dong, Baell, Jonathan, Noll, Benjamin D., Wang, Shudong, Kumar, Naresh, McArthur, Grant A., Cheung, Belamy B., Marshall, Glenn M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239542/
https://www.ncbi.nlm.nih.gov/pubmed/27447557
http://dx.doi.org/10.18632/oncotarget.10700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239542/
https://www.ncbi.nlm.nih.gov/pubmed/27447557
http://dx.doi.org/10.18632/oncotarget.10700

Ejemplares similares